Mortality Prediction in Diffuse Large B-Cell Lymphoma Using Supervised Machine Learning Models-A Retrospective Study.
Cosmin-Daniel Minciuna1, Dorina Minciuna2, Angela-Smaranda Dascalescu1
1Department of Hematology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Journal of Clinical Medicine
|November 27, 2025
Summary
Machine learning models, particularly Random Forest, show superior prediction of death in diffuse large B-cell lymphoma (DLBCL) patients compared to traditional methods. This aids in better risk stratification for personalized treatment strategies.
Area of Science:
- Oncology
- Biostatistics
- Computational Biology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous cancer with unpredictable patient outcomes.
- Accurate prognostic models are crucial for tailoring treatment and follow-up plans.
- Predicting patient survival at diagnosis is essential for effective clinical management.
Purpose of the Study:
- To evaluate the predictive performance of various machine learning (ML) models for 26-month mortality in DLBCL patients.
- To compare ML model efficacy against the traditional Cox proportional hazards model.
- To identify optimal modeling approaches for risk stratification in DLBCL.
Main Methods:
- Retrospective analysis of 412 DLBCL patients diagnosed and treated between 2015-2023.
- Utilized baseline clinical and paraclinical data for model training and testing.
- Compared six ML models (logistic regression, RF, SVM-RBF, MLP, RSF, XGBoost) with the Cox model.
Main Results:
- Random Forest (RF) demonstrated the highest predictive accuracy (AUC=0.9060, Accuracy=0.833, F1=0.902).
- XGBoost and MLP also showed strong performance, outperforming the Cox model (AUC=0.5561).
- RF and logistic regression exhibited the best model calibration.
Conclusions:
- Machine learning frameworks, especially RF, significantly outperform classical statistical models for DLBCL outcome prediction.
- These ML models offer a promising tool for enhancing risk assessment in DLBCL patients.
- The findings support the integration of advanced computational methods in clinical oncology.
Related Concept Videos
Cancer Survival Analysis
633
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633
Kaplan-Meier Approach
541
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
541


